Sumitomo Pharma
Japanese pharma selling CNS and oncology drugs, mostly through its US arm.
On the record
Checkpoint: Q1 FY2026 earnings, first read on price and volume erosion for ORGOVYX and GEMTESA
The call
Two US drugs carry most of the profit, and their exclusivity just ended, opening a multi-year window for generics to erode sales.
Sumitomo Pharma makes prescription medicines, with most recent profit coming from two US prostate and bladder drugs. These medicines are now losing legal protection from generics, meaning cheaper copies will flood the market within the next few years, erasing the company's main income stream. The company's only realistic lifeline is whether its experimental cancer and blood-disorder treatments (enzomenib, nuvisertib, and cell therapies) can reach patients and generate real sales before the old drugs collapse, which would need to happen by 2028.
Why
01
AI pressure: None apparent. AI has no visible role here; the pressure comes from generic drugmakers, not algorithms. Could AI do the core job? Unlikely.
02
Bigger players: Teva, Sandoz and other generic manufacturers. Exclusivity for ORGOVYX, GEMTESA and MYFEMBREE expired Dec 2025; generics can now file ANDAs and enter the US market. Could a giant copy it? Yes, easily.
03
What protects it. No generic version has launched yet, and pipeline drugs like enzomenib and nuvisertib could offset future erosion.
What would change this call
FDA Paragraph IV ANDA filings or approvals for ORGOVYX or GEMTESA within 12 months. Would confirm generic entry has begun eroding the two drugs funding the recovery.
Q1 FY2026 earnings (late July/August 2026) showing US revenue decline for ORGOVYX or GEMTESA. Would show price or volume erosion starting on schedule with exclusivity loss.
Phase 3 readouts for enzomenib or nuvisertib before 2028. Would show whether new pipeline can replace revenue lost to generics in time.
Q1 FY2026 earnings (late July/August 2026) showing US revenue decline for ORGOVYX or GEMTESA. Would show price or volume erosion starting on schedule with exclusivity loss.
Phase 3 readouts for enzomenib or nuvisertib before 2028. Would show whether new pipeline can replace revenue lost to generics in time.
Key numbers
- FY2025 revenue ¥453.294B, up 13.7% YoY
- FY2025 net profit ¥106.865B, up 352% YoY
- Overseas revenue ¥369.9B, 81.6% of total
Named risks
- Generic entry on ORGOVYX, GEMTESA, MYFEMBREE after Dec 2025 NCE expiry erodes core revenue.
- Revenue concentration in two US drugs (~$800M combined) with limited diversification.
- Repeated layoffs (2023, 2024) and early retirement signal ongoing structural instability.
- Capital-intensive cell therapy bets (¥10-12B/year burn) with uncertain 2030s payoff.
- Marubeni option to acquire remaining 40% of Asia business after 2029 reduces future control.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| AbbVie | contesting | Lupron remains entrenched incumbent versus ORGOVYX in prostate cancer, as of 2026 |
| Astellas/Pfizer | contesting | Xtandi and Myrbetriq compete directly with ORGOVYX and GEMTESA in oncology/OAB |
| Generic manufacturers (Teva, Sandoz) | gaining on | NCE exclusivity on ORGOVYX, GEMTESA, MYFEMBREE expired December 2025 |
| Mitsubishi Tanabe Pharma / Bain Capital | gaining on | Peer acquired by Bain Capital for ¥510B in Feb 2025, signaling faster sector consolidation |
Questions people ask
- Is Sumitomo Pharma profitable in 2026?
- Yes. For FY2025 (ended March 31, 2026), Sumitomo Pharma reported consolidated net profit of ¥106.865 billion, up 352% year over year, on revenue of ¥453.294 billion, per its financial results summary dated 2026-06-30. This follows net losses of roughly ¥96.7 billion in FY2023 and FY2024.
- Who owns Sumitomo Pharma?
- Sumitomo Pharma is publicly traded on the Tokyo Stock Exchange Prime Market (code 4506) and OTC in the US as DNPUF/SSUMY, but it remains majority controlled by its parent, Sumitomo Chemical Co., Ltd. It is not independently owned or VC backed.
- Will Sumitomo Pharma's ORGOVYX face generic competition soon?
- ORGOVYX, GEMTESA, and MYFEMBREE lost New Chemical Entity exclusivity in the US in December 2025, opening the door to generic entry. As of January 2026 no generic ANDAs had been approved yet, but the multi-year erosion window has begun, per a January 2026 patent-expiry analysis.
- Has Sumitomo Pharma had layoffs?
- Yes. Sumitomo Pharma cut about 500 US jobs in July 2023, announced roughly 400 more cuts at Sumitomo Pharma America in March 2024, and offered a Japan-based early-retirement program in July 2024 amid multi-year losses, per company news releases.
- Could AI replace Sumitomo Pharma's drug discovery work?
- Sumitomo Pharma uses Recursion's (formerly Exscientia's) AI platform for early molecule design, producing candidates like DSP-0038 and DSP-2342 disclosed May 2026, but clinical trials, regulatory approval, manufacturing, and sales networks remain human-run and are not AI-replaceable.
- Who is Sumitomo Pharma's biggest competitor?
- AbbVie (Lupron) and Astellas/Pfizer (Xtandi, Myrbetriq) are direct incumbents competing against Sumitomo Pharma's ORGOVYX in prostate cancer and GEMTESA in overactive bladder, the two drugs driving most of its FY2025 revenue.
Timeline
- 2026-06-30FY2025 results filed: revenue ¥453.294B, net profit ¥106.865B, up 352% YoY
- 2026-05-13Earnings call discloses AI-discovered pipeline compounds DSP-0038, DSP-2342 via Recursion
- 2026-03-02FY2025 revenue forecast revised up from ¥429.0B to ¥449.0B
- 2026-01-22Report confirms Dec 2025 NCE exclusivity expiry on 3 flagship drugs, no generics yet
- 2025-12NCE exclusivity expired for ORGOVYX, GEMTESA, MYFEMBREE in the US
- 2025-07-31Completed sale of 60% of Asia pharma business to Marubeni for ~¥45B
- 2024-08Exscientia merged into Recursion Pharmaceuticals, continuing AI drug discovery tie-up
- 2024-07-31Offered early-retirement program to Japan-based employees amid structural reforms
- 2024-03-04Announced ~400 further job cuts at Sumitomo Pharma America
- 2023-04-03Merged seven US subsidiaries into Sumitomo Pharma America, Inc.
Revision history
25 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Sumitomo Pharma Financial Results Summary (2026-06-30)
- Sumitomo Pharma Earnings Transcript (2026-05-13)
- Three Blockbuster Drugs Lose Regulatory Exclusivity (December 2025) (2026-01-22)
- ORGOVYX product brochure
- Sumitovant Biopharma Completes Acquisition of Myovant Sciences (2023-03-10)
- Sumitomo Pharma tidies up 7 units into one combined US entity (2023-04-03)
- Japan's Marubeni takes on Sumitomo's Asia pharma business in deal worth $300M (2025-04-02)
- Sumitomo Chemical to downsize drug and petrochemical businesses (2024-05-01)
- Sumitomo Pharma News Release (2024-03-04)
- Sumitomo Pharma News Release (2024-07-31)
- Sumitomo Pharma Employee Summary (2026-05-13)
- Wikipedia